3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
56
Breast Neoplasms
7
Bulbo-Spinal Atrophy, X-Linked
4
Neoplasms
3
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Salivary Gland Neoplasms
2
Stage I Prostate Adenocarcinoma
1
Recurrence
1
Paget Disease, Extramammary
1
PSA Level Greater Than Two
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Lower Urinary Tract Symptoms
1
Gynecomastia
1
Fallopian Tube Neoplasms
1
Erectile Dysfunction
1
Carcinoma, Transitional Cell
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms, Male
1
Adenocarcinoma
1
Interventions
Gemcitabine
12
Mitomycin
6
Docetaxel
4
Radiotherapy
3
BCG Vaccine
3
tislelizumab
2
erdafitinib
2
dodecyl maltoside
2
disitamab vedotin
2
toripalimab
1
pemigatinib
1
pembrolizumab
1
monalizumab
1
linrodostat
1
enzalutamide
1
durvalumab
1
bicalutamide
1
avelumab
1
Watchful Waiting
1
Sugars
1
Postoperative Period
1
Pentosan Sulfuric Polyester
1
Nonsteroidal Anti-Androgens
1
Nivolumab
1
Metformin
1
Imiquimod
1
Hyaluronic Acid
1
High-Intensity Interval Training
1
Gels
1
Epirubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Non-Muscle Invasive Bladder Neoplasms
×
bicalutamide
×
Clear all
NCT05327647
2025-12-18
BicaBCa
CHU de Quebec-Universite Laval
Phase 2
Recruiting
160 enrolled